Image Place holder

Nelli Bejanyan, MD

Specialty: Medical Oncology
Program: Blood and Marrow Transplant and Cellular Immunotherapy

Call 1-888-MOFFITT

Call 1-888-MOFFITT

Locations: Moffitt Cancer Center

Cancer Types Treated: MDS, Leukemia , Myelodysplastic Syndromes (MDS)

Dr. Nelli Bejanyan is an Associate Member in the Moffitt Cancer Center Department of Blood and Marrow Transplant and Cellular Immunotherapy. Dr. Bejanyan earned her MD summa cum laude from Yerevan State Medical University, Armenia. She completed an Internal Medicine Residency at Worcester Medical Center, Massachusetts (2005-2007) and the Cleveland Clinic Foundation, Ohio (2007-2008). From 2008-2009 Dr. Bejanyan was a Clinical and Research Fellow, Bone Marrow Failure Fellowship Program and a Hematology/Oncology Fellow at Taussig Cancer Institute, Cleveland Clinic. Dr. Bejanyan was most recently an Assistant Professor at the University of Minnesota, in the Bone Marrow Transplantation Division, where she served as the Chair of the Hematologic Malignancy Cancer Care Leukemia Team. Dr. Bejanyan’s clinical interests are in BMT for acute myeloid leukemia, myelodysplastic syndromes and haploidentical stem cell transplantation. Her research interests are improved stem cell transplantation for myeloid malignancies, including strategies for relapse prevention, improvement of conditioning regimens and immune reconstitution. She is also interested in improved outcomes associated with alternative donor transplantation for patients with hematologic malignancies. 

Education & Training

Board Certification:

  • Hematology
  • Internal Medicine
  • Medical Oncology


  • Taussig Cancer Center - Hematology & Medical Oncology


  • University of Medical Center - Surgery
  • Worcester Medical Center - Internal Medicine
  • Cleveland Clinic Foundation - Internal Medicine

Medical School:

  • Yerevan State Medical University - MD
Participating Trials

A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma In Minimal Residual Disease-Negative First Complete Remission
Condition: Malignant Hematology
Intervention: Rituxan (rituximab); Rituxan Hycela; rituximab

A Phase 2, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of KD025 in Subjects with Chronic Graft Versus Host Disease (cGVHD) After At Least 2 Prior Lines of Systemic Therapy (The ROCKstar Study)
Condition: Malignant Hematology
Intervention: KD025

A Phase 1B/2 Study To Evaluate The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, And Clinical Activity Of Eq001 In Subjects With Newly Diagnosed Acute Graft Versus Host Disease
Condition: Malignant Hematology
Intervention: EQ001; Placebo

Phase II trial of APR-246 in combination with azacitidine as maintenance therapy for TP53 mutated AML or MDS following allogeneic stem cell transplant
Condition: Malignant Hematology
Intervention: APR-246; azacitidine (5-azacitidine)

Improving Allogeneic Transplant Outcomes Through Enhanced AMPK-mediated Immune Reconstitution and T-cell Response Modulation
Condition: Malignant Hematology
Intervention: Metformin

A Randomized, Multicenter, Phase III Trial of Tacrolimus/Methotrexate versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation
Condition: Malignant Hematology
Intervention: Cellcept (Mycophenolate Mofetil); FK506 (Tacrolimus); Mycophenolate Mofetil; Tacrolimus; cyclophosphamide; cytoxan (cyclophosphamide); methotrexate

Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (CTRL-ALT-D)
Condition: Malignant Hematology

An Open-Label, Phase I/II Study to Assess the Safety and Clinical Activity of NKR-2 Treatment Administration after a Non-Myeloablative Preconditioning Chemotherapy in Relapse/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients.
Condition: Malignant Hematology
Intervention: NKR-2

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.


  • Ahmed S, Kanakry JA, Ahn KW, Litovich C, Abdel-Azim H, Aljurf M, Bacher VU, Bejanyan N, Cohen JB, Farooq U, Fuchs EJ, Bolaños-Meade J, Ghosh N, Herrera AF, Hossain NM, Inwards D, Kanate AS, Martino R, Munshi PN, Murthy H, Mussetti A, Nieto Y, Perales MA, Romee R, Savani BN, Seo S, Wirk B, Yared JA, Sureda A, Fenske TS, Hamadani M. Lower Graft-versus-Host Disease and Relapse Risk in Post-Transplant Cyclophosphamide-Based Haploidentical versus Matched Sibling Donor Reduced-Intensity Conditioning Transplant for Hodgkin Lymphoma. Biol Blood Marrow Tr. 2019 May;25(9):1859-1868. Pubmedid: 31132455. Pmcid: PMC6755039.
  • Holtan SG, Zhang L, DeFor TE, Bejanyan N, Arora M, Rashidi A, Lazaryan A, Kotiso F, Blazar BR, Wagner JE, Brunstein CG, MacMillan ML, Weisdorf DJ. Dynamic Graft-versus-Host Disease-Free, Relapse-Free Survival: Multistate Modeling of the Morbidity and Mortality of Allotransplantation. Biol Blood Marrow Tr. 2019 May;25(9):1884-1889. Pubmedid: 31128328. Pmcid: PMC6755055.
  • Brunstein CG, Pasquini MC, Kim S, Fei M, Adekola K, Ahmed I, Aljurf M, Agrawal V, Auletta JJ, Battiwalla M, Bejanyan N, Bubalo J, Cerny J, Chee L, Ciurea SO, Freytes C, Gadalla SM, Gale RP, Ganguly S, Hashmi SK, Hematti P, Hildebrandt G, Holmberg LA, Lahoud OB, Landau H, Lazarus HM, de Lima M, Mathews V, Maziarz R, Nishihori T, Norkin M, Olsson R, Reshef R, Rotz S, Savani B, Schouten HC, Seo S, Wirk BM, Yared J, Mineishi S, Rogosheske J, Perales MA. Effect of Conditioning Regimen Dose Reduction in Obese Patients Undergoing Autologous Hematopoietic Cell Transplantation. Biol Blood Marrow Tr. 2019 Mar;25(3):480-487. Pubmedid: 30423481. Pmcid: PMC6445718.
  • Rashidi A, Hamadani M, Zhang MJ, Wang HL, Abdel-Azim H, Aljurf M, Assal A, Bajel A, Bashey A, Battiwalla M, Beitinjaneh AM, Bejanyan N, Bhatt VR, Bolaños-Meade J, Byrne M, Cahn JY, Cairo M, Ciurea S, Copelan E, Cutler C, Daly A, Diaz MA, Farhadfar N, Gale RP, Ganguly S, Grunwald MR, Hahn T, Hashmi S, Hildebrandt GC, Holland HK, Hossain N, Kanakry CG, Kharfan-Dabaja MA, Khera N, Koc Y, Lazarus HM, Lee JW, Maertens J, Martino R, McGuirk J, Munker R, Murthy HS, Nakamura R, Nathan S, Nishihori T, Palmisiano N, Patel S, Pidala J, Olin R, Olsson RF, Oran B, Ringden O, Rizzieri D, Rowe J, Savoie ML, Schultz KR, Seo S, Shaffer BC, Singh A, Solh M, Stockerl-Goldstein K, Verdonck LF, Wagner J, Waller EK, De Lima M, Sandmaier BM, Litzow M, Weisdorf D, Romee R, Saber W. Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission. Blood Adv. 2019 Jun;3(12):1826-1836. Pubmedid: 31201170. Pmcid: PMC6595262.
  • Warlick ED, DeFor TE, Bejanyan N, Holtan S, MacMillan M, Blazar BR, Dusenbery K, Arora M, Bachanova V, Cooley S, Lazaryan A, McGlave P, Miller JS, Rashidi A, Slungaard A, Vercellotti G, Ustun C, Brunsein C, Weisdorf D. Reduced-Intensity Conditioning Followed by Related and Unrelated Allografts for Hematologic Malignancies: Expanded Analysis and Long-Term Follow-Up. Biol Blood Marrow Tr. 2019 Jan;25(1):56-62. Pubmedid: 30077015. Pmcid: PMC6310652.
  • Bejanyan N, Brunstein CG, Cao Q, Lazaryan A, Ustun C, Warlick ED, Arora M, Wagner JE, Weisdorf DJ. Predictive value of disease risk comorbidity index for overall survival after allogeneic hematopoietic transplantation. Blood Adv. 2019 Feb;3(3):230-236. Pubmedid: 30674457. Pmcid: PMC6373743.
  • He F, Sapkota S, Parker S, Defor T, Warlick E, Ustun C, Eckfeldt C, Rashidi A, Kurtzweil A, Weisdorf D, Bejanyan N. A real-world study of clofarabine and cytarabine combination therapy for patients with acute myeloid leukemia. Leuk Lymphoma. 2018 Oct;59(10):2352-2359. Pubmedid: 29415603.
  • Rashidi A, Ebadi M, Said B, Cao Q, Shanley R, Curtsinger J, Bejanyan N, Warlick ED, Green JS, Brunstein CG, Miller JS, Weisdorf DJ. Absence of early HHV-6 reactivation after cord blood allograft predicts powerful graft-versus-tumor effect. Am J Hematol. 2018 May. Pubmedid: 29756385. Pmcid: PMC6235732.
  • Ustun C, Brunstein C, DeFor T, Rashidi A, Yohe S, Bejanyan N, Cooley S, Warlick E, Miller J, Linden MA, Weisdorf D. Importance of conditioning regimen intensity, MRD positivity, and KIR ligand mismatch in UCB transplantation. Bone Marrow Transplant. 2018 Jan;53(1):97-100. Pubmedid: 28991246.
  • Keklik F, Alrawi EB, Cao Q, Bejanyan N, Rashidi A, Lazaryan A, Arndt P, Dincer EH, Bachanova V, Warlick ED, MacMillan ML, Arora M, Miller J, Brunstein CG, Weisdorf DJ, Ustun C. Diffuse alveolar hemorrhage is most often fatal and is affected by graft source, conditioning regimen toxicity, and engraftment kinetics. Haematologica. 2018 Dec;103(12):2109-2115. Pubmedid: 30076172. Pmcid: PMC6269296.
  • Kebriaei P, Anasetti C, Zhang MJ, Wang HL, Aldoss I, de Lima M, Khoury HJ, Sandmaier BM, Horowitz MM, Artz A, Bejanyan N, Ciurea S, Lazarus HM, Gale RP, Litzow M, Bredeson C, Seftel MD, Pulsipher MA, Boelens JJ, Alvarnas J, Champlin R, Forman S, Pullarkat V, Weisdorf D, Marks DI. Intravenous Busulfan Compared with Total Body Irradiation Pretransplant Conditioning for Adults with Acute Lymphoblastic Leukemia. Biol Blood Marrow Tr. 2018 Apr;24(4):726-733. Pubmedid: 29197676. Pmcid: PMC5902420.
  • Rashidi A, Weisdorf DJ, Bejanyan N. Treatment of relapsed/refractory acute myeloid leukaemia in adults. Brit J Haematol. 2018 Apr;181(1):27-37. Pubmedid: 29318584.
  • Bejanyan N, Brunstein CG, Cao Q, Lazaryan A, Luo X, Curtsinger J, Mehta RS, Warlick E, Cooley SA, Blazar BR, Miller JS, Weisdorf D, Wagner JE, Verneris MR. Delayed immune reconstitution after allogeneic transplantation increases the risks of mortality and chronic GVHD. Blood Adv. 2018 Apr;2(8):909-922. Pubmedid: 29678809. Pmcid: PMC5916001.
  • Shah NN, Ahn KW, Litovich C, Fenske TS, Ahmed S, Battiwalla M, Bejanyan N, Dahi PB, Bolaños-Meade J, Chen AI, Ciurea SO, Bachanova V, DeFilipp Z, Epperla N, Farhadfar N, Herrera AF, Haverkos BM, Holmberg L, Hossain NM, Kharfan-Dabaja MA, Kenkre VP, Lazarus HM, Murthy HS, Nishihori T, Rezvani AR, D'Souza A, Savani BN, Ulrickson ML, Waller EK, Sureda A, Smith SM, Hamadani M. Outcomes of Medicare-age eligible NHL patients receiving RIC allogeneic transplantation: a CIBMTR analysis. Blood Adv. 2018 Apr;2(8):933-940. Pubmedid: 29685953. Pmcid: PMC5916010.
  • Belete H, Burns LJ, Shanley R, Nayar M, McClune B, Lazaryan A, Bachanova V, Bejanyan N, Ustun C, Brunstein C, Weisdorf DJ, Arora M. Transplantation related toxicity and mortality in older autologous hematopoietic cell transplantation recipients. Am J Hematol. 2017 Sep;92(9):E529-E533. Pubmedid: 28612451. Pmcid: PMC5733686.
  • He F, Cao Q, Lazaryan A, Brunstein C, Holtan S, Warlick E, Ustun C, McClune B, Arora M, Rashidi A, Eckfeldt C, Weisdorf DJ, Bejanyan N. Allogeneic Hematopoietic Cell Transplantation for Older Patients: Prognosis Determined by Disease Risk Index. Biol Blood Marrow Tr. 2017 Sep;23(9):1485-1490. Pubmedid: 28522345. Pmcid: PMC5586072.
  • Rashidi A, Linden MA, DeFor TE, Warlick E, Bejanyan N, Yohe S, Weisdorf DJ, Ustun C. History of consolidation is prognostic in acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplantation in minimal residual disease-negative first complete remission. Am J Hematol. 2017 Oct;92(10):1032-1036. Pubmedid: 28646534. Pmcid: PMC5734672.
  • Bejanyan N. Is It All About Age or Personalized Haploidentical Hematopoietic Stem Cell Transplantation for Elderly Patients?. Biol Blood Marrow Tr. 2017 Oct;23(10):1602-1604. Pubmedid: 28842387.
  • Brunstein CG, Cutler CS, DeFor TE, Kim H, Bejanyan N, Garfall A, Verneris MR, Chen YB, Warlick ED, Spitzer T, Miller JS, Antin JH, Weisdorf DJ, Soiffer R, Wagner JE, Ballen KK. Matching at Human Leukocyte Antigen-C Improved the Outcomes after Double Umbilical Cord Blood Transplantation for Recipients of Two to Four of Six Human Leukocyte Antigen-Matched Grafts. Biol Blood Marrow Tr. 2017 Jan;23(1):126-133. Pubmedid: 27989929. Pmcid: PMC5510875.
  • Pourhassan H, DeFor T, Trottier B, Dolan M, Brunstein C, Bejanyan N, Ustun C, Warlick ED. MDS disease characteristics, not donor source, predict hematopoietic stem cell transplant outcomes. Bone Marrow Transplant. 2017 Apr;52(4):532-538. Pubmedid: 27941767. Pmcid: PMC5382091.
  • Bejanyan N, Rogosheske J, DeFor TE, Lazaryan A, Arora M, Holtan SG, Jacobson PA, MacMillan ML, Verneris MR, Blazar BR, Weisdorf DJ, Wagner JE, Brunstein CG. Sirolimus and Mycophenolate Mofetil as Calcineurin Inhibitor-Free Graft-versus-Host Disease Prophylaxis for Reduced-Intensity Conditioning Umbilical Cord Blood Transplantation. Biol Blood Marrow Tr. 2016 Nov;22(11):2025-2030. Pubmedid: 27519278. Pmcid: PMC5067231.
  • Omer AK, Weisdorf DJ, Lazaryan A, Shanley R, Blazar BR, MacMillan ML, Brunstein C, Bejanyan N, Arora M. Late Acute Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Tr. 2016 May;22(5):879-883. Pubmedid: 26743342. Pmcid: PMC4922492.
  • Mehta RS, Peffault de Latour R, DeFor TE, Robin M, Lazaryan A, Xhaard A, Bejanyan N, de Fontbrune FS, Arora M, Brunstein CG, Blazar BR, Weisdorf DJ, MacMillan ML, Socie G, Holtan SG. Improved graft-versus-host disease-free, relapse-free survival associated with bone marrow as the stem cell source in adults. Haematologica. 2016 Jun;101(6):764-772. Pubmedid: 27036159. Pmcid: PMC5013959.
  • Lazaryan A, Weisdorf DJ, DeFor T, Brunstein CG, MacMillan ML, Bejanyan N, Holtan S, Blazar BR, Wagner JE, Arora M. Risk Factors for Acute and Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation with Umbilical Cord Blood and Matched Sibling Donors. Biol Blood Marrow Tr. 2016 Jan;22(1):134-140. Pubmedid: 26365153. Pmcid: PMC4787268.
  • Sandhu KS, Brunstein C, DeFor T, Bejanyan N, Arora M, Warlick E, Weisdorf D, Ustun C. Umbilical Cord Blood Transplantation Outcomes in Acute Myelogenous Leukemia/Myelodysplastic Syndrome Patients Aged ≥70 Years. Biol Blood Marrow Tr. 2016 Feb;22(2):390-393. Pubmedid: 26415559. Pmcid: PMC4768714.
  • Eckfeldt CE, Randall N, Shanley RM, Yohe S, Bejanyan N, Dolan M, Warlick ED, Verneris MR, Brunstein CG, Wagner JE, Weisdorf DJ, Ustun C. Umbilical cord blood transplantation is a suitable option for consolidation of acute myeloid leukemia with FLT3-ITD. Haematologica. 2016 Aug;101(8):e348-e351. Pubmedid: 27125981. Pmcid: PMC4967587.
  • Ustun C, Courville EL, DeFor T, Dolan M, Randall N, Yohe S, Bejanyan N, Warlick E, Brunstein C, Weisdorf DJ, Linden MA. Myeloablative, but not Reduced-Intensity, Conditioning Overcomes the Negative Effect of Flow-Cytometric Evidence of Leukemia in Acute Myeloid Leukemia. Biol Blood Marrow Tr. 2016 Apr;22(4):669-675. Pubmedid: 26551635. Pmcid: PMC4805453.
  • Lund TC, Liegel J, Bejanyan N, Orchard PJ, Cao Q, Tolar J, Brunstein C, Wagner JE, Verneris MR, Weisdorf D. Second allogeneic hematopoietic cell transplantation for graft failure: poor outcomes for neutropenic graft failure. Am J Hematol. 2015 Oct;90(10):892-896. Pubmedid: 26149534. Pmcid: PMC4579006.
  • Lunde LE, Dasaraju S, Cao Q, Cohn CS, Reding M, Bejanyan N, Trottier B, Rogosheske J, Brunstein C, Warlick E, Young JA, Weisdorf DJ, Ustun C. Hemorrhagic cystitis after allogeneic hematopoietic cell transplantation: risk factors, graft source and survival. Bone Marrow Transplant. 2015 Nov;50(11):1432-1437. Pubmedid: 26168069. Pmcid: PMC5343753.
  • Bejanyan N, Rogosheske J, DeFor T, Lazaryan A, Esbaum K, Holtan S, Arora M, MacMillan ML, Weisdorf D, Jacobson P, Wagner J, Brunstein CG. Higher Dose of Mycophenolate Mofetil Reduces Acute Graft-versus-Host Disease in Reduced-Intensity Conditioning Double Umbilical Cord Blood Transplantation. Biol Blood Marrow Tr. 2015 May;21(5):926-933. Pubmedid: 25655791. Pmcid: PMC4768800.
  • Bejanyan N, Weisdorf DJ, Logan BR, Wang HL, Devine SM, de Lima M, Bunjes DW, Zhang MJ. Survival of patients with acute myeloid leukemia relapsing after allogeneic hematopoietic cell transplantation: a center for international blood and marrow transplant research study. Biol Blood Marrow Tr. 2015 Mar;21(3):454-459. Pubmedid: 25460355. Pmcid: PMC4329076.
  • Bejanyan N, Haddad H, Brunstein C. Alternative Donor Transplantation for Acute Myeloid Leukemia. J Clin Med. 2015 Jun;4(6):1240-1268. Pubmedid: 26239557. Pmcid: PMC4484998.
  • Warlick ED, Peffault de Latour R, Shanley R, Robin M, Bejanyan N, Xhaard A, Brunstein C, Sicre de Fontbrune F, Ustun C, Weisdorf DJ, Socie G. Allogeneic hematopoietic cell transplantation outcomes in acute myeloid leukemia: similar outcomes regardless of donor type. Biol Blood Marrow Tr. 2015 Feb;21(2):357-363. Pubmedid: 25452032. Pmcid: PMC4736537.
  • Holtan SG, DeFor TE, Lazaryan A, Bejanyan N, Arora M, Brunstein CG, Blazar BR, MacMillan ML, Weisdorf DJ. Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation. Blood. 2015 Feb;125(8):1333-1338. Pubmedid: 25593335. Pmcid: PMC4335084.
  • Gupta V, Malone AK, Hari PN, Ahn KW, Hu ZH, Gale RP, Ballen KK, Hamadani M, Olavarria E, Gerds AT, Waller EK, Costa LJ, Antin JH, Kamble RT, van Besien KM, Savani BN, Schouten HC, Szer J, Cahn JY, de Lima MJ, Wirk B, Aljurf MD, Popat U, Bejanyan N, Litzow MR, Norkin M, Lewis ID, Hale GA, Woolfrey AE, Miller AM, Ustun C, Jagasia MH, Lill M, Maziarz RT, Cortes J, Kalaycio ME, Saber W. Reduced-intensity hematopoietic cell transplantation for patients with primary myelofibrosis: a cohort analysis from the center for international blood and marrow transplant research. Biol Blood Marrow Tr. 2014 Jan;20(1):89-97. Pubmedid: 24161923. Pmcid: PMC3886623.
  • Bejanyan N, Oran B, Shanley R, Warlick E, Ustun C, Vercellotti G, Verneris M, Wagner JE, Weisdorf D, Brunstein C. Clinical outcomes of AML patients relapsing after matched-related donor and umbilical cord blood transplantation. Bone Marrow Transplant. 2014 Aug;49(8):1029-1035. Pubmedid: 24887379. Pmcid: PMC4768798.
  • Bejanyan N, Bolwell BJ, Lazaryan A, Rybicki L, Tench S, Duong H, Andresen S, Sobecks R, Dean R, Pohlman B, Kalaycio M, Copelan EA. Risk factors for 30-day hospital readmission following myeloablative allogeneic hematopoietic cell transplantation (allo-HCT). Biol Blood Marrow Tr. 2012 Jun;18(6):874-880. Pubmedid: 22040844.
  • Bejanyan N, Tiu RV, Raza A, Jankowska A, Kalaycio M, Advani A, Chan J, Saunthararajah Y, Mooney L, Maciejewski JP, Sekeres MA. A phase 2 trial of combination therapy with thalidomide, arsenic trioxide, dexamethasone, and ascorbic acid (TADA) in patients with overlap myelodysplastic/myeloproliferative neoplasms (MDS/MPN) or primary myelofibrosis (PMF). Cancer. 2012 Aug;118(16):3968-3976. Pubmedid: 22180010.
  • Clemente MJ, Wlodarski MW, Makishima H, Viny AD, Bretschneider I, Shaik M, Bejanyan N, Lichtin AE, Hsi ED, His ED, Paquette RL, Loughran TP, Maciejewski JP. Clonal drift demonstrates unexpected dynamics of the T-cell repertoire in T-large granular lymphocyte leukemia. Blood. 2011 Oct;118(16):4384-4393. Pubmedid: 21865345. Pmcid: PMC3204910.
  • Sekeres MA, Bejanyan N. The revolution of myelodysplastic syndromes. Ther Adv Hematol. 2011 Feb;2(1):33-43. Pubmedid: 23556074. Pmcid: PMC3573393.
  • Howard MT, Bejanyan N, Maciejewski JP, Hsi ED. T/NK large granular lymphocyte leukemia and coexisting monoclonal B-cell lymphocytosis-like proliferations. An unrecognized and frequent association. Am J Clin Pathol. 2010 Jun;133(6):936-941. Pubmedid: 20472852.
  • Jasek M, Gondek LP, Bejanyan N, Tiu R, Huh J, Theil KS, O'Keefe C, McDevitt MA, Maciejewski JP. TP53 mutations in myeloid malignancies are either homozygous or hemizygous due to copy number-neutral loss of heterozygosity or deletion of 17p. Leukemia. 2010 Jan;24(1):216-219. Pubmedid: 19759556. Pmcid: PMC2806506.
  • Bejanyan N, Fu AZ, Lazaryan A, Fu R, Kalaycio M, Advani A, Sobecks R, Copelan E, Maciejewski JP, Sekeres MA. Impact of weekend admissions on quality of care and outcomes in patients with acute myeloid leukemia. Cancer. 2010 Aug;116(15):3614-3620. Pubmedid: 20564070.
  • Szpurka H, Jankowska AM, Makishima H, Bodo J, Bejanyan N, Hsi ED, Sekeres MA, Maciejewski JP. Spectrum of mutations in RARS-T patients includes TET2 and ASXL1 mutations. Leuk Res. 2010 Aug;34(8):969-973. Pubmedid: 20334914. Pmcid: PMC2953471.
  • Mohan SR, Clemente MJ, Afable M, Cazzolli HN, Bejanyan N, Wlodarski MW, Lichtin AE, Maciejewski JP. Therapeutic implications of variable expression of CD52 on clonal cytotoxic T cells in CD8+ large granular lymphocyte leukemia. Haematologica. 2009 Oct;94(10):1407-1414. Pubmedid: 19794084. Pmcid: PMC2754957.